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PARP INHIBITOR UPREGULATES PD-L1 EXPRESSION AND ENHANCES 
CANCER-ASSOCIATED IMMUNOSUPPRESSION  
Abstract 
Shiping Jiao, M.D. 
Advisory Professor: Mien-Chie Hung, Ph.D. 
With recent approvals for therapeutic antibodies that block CTLA4, PD-1 and 
PD-L1, immune checkpoints have emerged as new targets in cancer therapy. In addition, 
there is accumulating evidence highlighting the role of cancer-associated immunity in 
patient response to cytotoxic anticancer agents. Inhibitors of poly (ADP-ribose) 
polymerase (PARP) have shown substantial cytotoxic effects against tumors with defects 
in DNA damage responses. However, whether a crosstalk between PARP inhibition and 
immune checkpoints exists remains unclear. Here, it has been shown that PARP 
inhibitors (PARPis) upregulate PD-L1 expression in multiple cancer cell lines, human 
xenograft tumors and syngeneic mouse tumors. Mechanistically, PARPi inactivates 
GSK3β, which in turn enhances PARPi-mediated PD-L1 upregulation. PARPi attenuates 
anticancer immunity via upregulation of PD-L1, and blockade of PD-L1 re-sensitizes 
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PARPi-treated cancer cells to T cell killing. The combination of PARPi and anti-PD-L1 
therapy compared with each agent alone significantly increased the therapeutic efficacy 
in vivo. In details, PARPi treatment increases T lymphocytes infiltration in tumors; 
however the induced PD-L1 by PARPi on cancer cells inhibits the activation of the 
infiltrating T lymphocytes. Thus, the addition of PD-L1 blockade to PARPi therapy can 
re-activate anti-tumor immunity and improve the therapeutic efficacy. This study 
demonstrates a crosstalk between PARPi and tumor-associated immunosuppression, and 
provides a rationale for the combination of PARPi and PD-L1 or PD-1 immune 
checkpoint blockade as a potential therapeutic approach. (Jiao et al., 2017)  
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Chapter 1 Introduction 
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1.1 PARP and PARP inhibitor 
Poly (ADP-ribose) polymerase (PARP) engages in DNA base excision repair by 
inducing poly (ADP-ribosy)lation of itself and other target proteins (Sonnenblick et al., 
2015). In addition, PARP has a less well-defined role in homologous recombination 
mediated (Bryant et al., 2009) and alternative non-homologous end-joining mediated 
double-strand break repair (Paddock et al., 2011). PARP inhibition has been shown to be an 
effective therapeutic strategy against tumors associated with germline mutations in 
double-strand DNA repair genes by inducing synthetic lethality (Sonnenblick et al., 2015). 
One PARP inhibitor (PARPi), olaparib, was approved by the U.S. Food and Drug 
Administration (FDA) in 2014 for the treatment of germline BRCA-mutated (gBRCAm) 
advanced ovarian cancer (Kim et al., 2015). More recently, another PARPi, niraparib, which 
was shown to significantly prolong the progression-free survival in ovarian cancer patients, 
received a fast track designation from the FDA for the treatment of patients with recurrent 
platinum-sensitive ovarian cancer (Mirza et al., 2016).  
 
1.2 Combination strategies to potentiate PARP inhibitor 
In addition to ovarian cancer, PARPi has demonstrated tremendous potential in breast 
cancer, and there are currently several active clinical trials evaluating PARPi-containing 
3 
combination therapies for advanced breast cancer. Although the objective response rate to 
PARPi in patients with advanced breast cancer harboring BRCA1/2 mutations was reported 
as high as 41%, its response duration is still very limited with a 5.7-month median duration 
(Tutt et al., 2010). The underlying resistance mechanisms to PARPi have mainly attributed to 
the restoration of double-strand break repair. For instance, secondary BRCA mutations that 
restore BRCA function (Edwards et al., 2008) and reduced 53BP1 expression leading to 
partial restoration of homologous recombination (Jaspers et al., 2013) have been described 
as the potential resistance mechanisms to PARPi. In order to enhance the cytotoxic effect of 
PARPi, several combinations of PARPi and targeted anticancer agents, such as inhibitors 
against phosphatidylinositol 3-kinase (Ibrahim et al., 2012; Juvekar et al., 2012), Wee1 
kinase (Karnak et al., 2014), DNA topoisomerase I (Kummar et al., 2011), and DNA 
methyltransferase (Muvarak et al., 2016), have been proposed. In addition, c-Met-mediated 
phosphorylation of PARP was reported to contribute to PARPi resistance, suggesting that the 
combined inhibition of c-Met and PARP may benefit patients who do not respond to PARPi 
and whose tumors are associated with c-Met activation (Du et al., 2016). Thus, developing a 
rational combination therapy with PARPi may lead to effective anticancer strategy. 
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1.3 Cancer-associated immunity and immune checkpoint therapy 
Over the last few years, there have been major breakthroughs in our understanding of 
tumor-associated immunosuppression. A key mechanism underlying cancer immune evasion 
is the expression of multiple inhibitory ligands, notably PD-L1, on the surface of cancer 
cells. Engagement of the PD-1 receptor on T cells by PD-L1 leads to the suppression of T 
cell proliferation, cytokine release, and cytolytic activity whereas blockade of co-inhibitory 
ligation with monoclonal antibodies, such as PD-L1 or PD-1 antibodies, restores T cell 
function and increases therapeutic efficacy (Dong et al., 2002; Freeman et al., 2000). The 
impressive and durable clinical response of checkpoint blockade immunotherapy resulted in 
the FDA approval of ipilimumab, nivolumab, pembrolizumab, and more recently 
atezolizumab for the treatment of multiple types of cancer, such as melanoma, Hodgkin’s 
lymphoma, and lung and bladder cancers ((Garon et al., 2015; Hodi, 2010; Robert et al., 
2015; Rosenberg et al., 2016)). Notably, the PD-1 antibody pembrolizumab was approved as 
first-line treatment for patients with advanced non-small cell lung cancer and high PD-L1 
expression (Reck et al., 2016).  
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1.4 Cytotoxic anticancer agents and cancer-associated immunity 
There is accumulating evidence indicating that conventional and targeted anticancer 
therapies also affect tumor-targeting immune responses (Galluzzi et al., 2015). Thus, 
delineating the crosstalk between cytotoxic anticancer agents and cancer-associated 
immunity may lead to more efficient combinatorial regimens. Although the effects of PARPi, 
a targeted anticancer agent, have shown promising results in multiple cancer types, how and 
whether PARPi plays a role in cancer-associated immunity is still unknown. In the current 
study, I investigate the crosstalk between PARP inhibition and immune checkpoint, in 
particular, the PD-L1/PD-1 axis, which is a dominant immune checkpoint pathway in the 
tumor microenvironment, and further explore a mechanism-driven combination strategy to 
potentiate PARPi.  
  
6 
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2.1 Cell lines   
All cell lines were obtained from ATCC (Manassas, VA) and have been independently 
validated by STR DNA fingerprinting at MD Anderson Cancer Center. PARP1 (#sc-400046), 
PD-L1 (#sc-401140), and GSK3β (#sc-425249) knockout cells were established using 
CRISPR/Cas9 KO plasmids from Santa Cruz Biotechnology (Dallas, TX). PARP1 
knockdown MDA-MB-231 cells were established as described previously (Du et al., 2016).  
 
2.2 Antibodies and Chemicals 
PD-L1 (#13684), PARP1 (#9532), phospho-GSK3β (Ser9, #9336), GSK3β (#9315), 
Ki-67 (#9449) antibodies were purchased from Cell Signaling Technology, BRCA1 (sc-8326) 
and BRCA2 (sc-642) were from Santa Cruz, and α-Tubulin (#B-5-1-2) and β-Actin (#A2228) 
were obtained from Sigma-Aldrich (St. Louis, MO). CD3 (ab5690) were purchased from 
Abcam. Olaparib, rucaparib, and talazoparib were purchased from Selleckchem (Houston, 
TX), ChemieTek (Indianapolis, IN), and Selleckchem, respectively. The Human 
Phospho-Kinase Array Kit (#ARY003B) was purchased from R&D Systems (Minneapolis, 
MN) and human CD274 (B7-H1, PD-L1) antibody for T-cell killing assay was from 
BioLegend (#329709). eSiRNA human BRCA1 (EHU096311), eSiRNA human BRCA2 
(EHU031451) and siRNA universal negative control (SIC001) were from Sigma-Aldrich.  
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2.3 Human phospho-kinase antibody array 
The Human Phospho-Kinase Array Kit (#ARY003B) was from R&D Systems 
(Minneapolis, MN). Array screening was performed following the manufacturer’s manuals. 
In brief, cell lysates were incubated with the array membranes. After washing, membranes 
were incubated with biotinylated antibody cocktail. The amounts of phospho-kinase were 
assessed with streptavidin conjugated to horseradish peroxidase, followed by 
chemiluminescence detection. The software GS-800 Calibrated Densitometer (Bio-Rad 
Laboratories, CA) was utilized to quantify the density of each dot against the average of the 
internal controls on the membrane as indicated in the protocol. 
 
2.4 Detection of cell surface PD-L1 
For detection of cell surface PD-L1, cells were suspended in 100 µl of cell staining 
buffer (#420201, BioLegend) and incubated with APC conjugated anti-human PD-L1 
antibody (#329708, BioLegend) at room temperature for 30 min. After washing in the 
staining buffer, stained cells were analyzed by fluorescence-activated cell sorting (FACS; 
BD Biosciences).  
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2.5 PD-L1/PD-1 binding assay    
Cells (1 x 106) were incubated with 5 µg/ml recombinant human PD-1 FC chimera 
protein (#1086-PD-050, R&D Systems) at room temperature for 30 min. After washing in 
staining buffer, cells were incubated with anti-human Alexa Fluor 488 dye conjugated 
antibody (ThermoFisher Scientific) at room temperature for 30 min. Cells were analyzed by 
FACS after wash in the staining buffer. The FASC data was analyzed using Flowjo (Tree star, 
CA), and the cutoff line for relative positive percentage was set at the median of the 
maximum signal. 
 
2.6 T-cell killing assay 
NucLight RFP MDA-MB-231 cells (#4457, Essen Bioscience, Ann Arbor, MI) were 
seeded in a 96-well plate with or without olaparib. Human peripheral blood mononuclear 
cells (PBMCs; #70025, STEMCELL, Vancouver, BC, Canada) were activated with 100 
ng/ml CD3 antibody, 100 ng/ml CD28 antibody and 10 ng/ml IL-2 (#317303; #302913; 
#589102, BioLegend, San Diego, CA) and then co-cultured with MDA-MB-231 cells at 
10:1 ratio in the presence of fluorescence caspase 3/7 substrate (#4440, Essen Bioscience). 
10 
 
2.7 PD-L1 detection in xenograft tumors 
All animal procedures were conducted under the guidelines approved by the 
Institutional Animal Care and Use Committee (IACUC) at UT MD Anderson Cancer Center. 
MDA-MB-231 (0.5 × 106), BT549 (1 × 106) or SUM149 (2 × 106) cells in Matrixgel (BD 
Biosciences, San Jose, CA) were inoculated in the mammary fat pads of nude mice (6 – 8 
weeks, female). When tumor volume reached ~50 mm3, mice were administered olaparib 
(25 mg/kg) or rucaparib (5 mg/kg) orally 5 days per week for three weeks. Tumors were 
harvested after final treatment, and analyzed by immunoblotting and immunohistochemistry 
(IHC). IHC staining was as described previously (Xia et al., 2004). Briefly, frozen tissue 
sections were fixed with 4% paraformaldehyde for 1 hour and then hydrated in PBS for 5 
min at room temperature (RT). Sections were permeabilized with 0.5% triton X-100 for 15 
min at RT. The endogenous peroxidase activity was blocked with 0.3% hydrogen peroxide in 
methanol for 15 min at RT. After serum blocking, the slides were incubated overnight at 4 
°C with human PD-L1 antibody (#13684, Cell Signaling Technology, 1:50 dilution). Slides 
were then incubated with biotinylated secondary antibodies for 1 hour at RT, followed by 
incubation with avidin-biotin-horseradish peroxidase complex. Visualization was performed 
11 
using 0.125% amino-ethylcarbazole chromogen. After counterstaining with Mayer’s 
hematoxylin, slides were mounted. 
2.8 Syngeneic tumor model treatment protocol    
BALB/c mice (6–8 week female, Jackson Laboratories, Bar Harbor, Maine) were 
inoculated in the mammary fat pads with EMT6 (1 × 105) cells in Matrixgel. On days 3 after 
the inoculation, mice were injected intraperitoneally with 50 mg/kg olaparib or vehicle daily. 
After days 4, mice were injected intraperitoneally every 4 days with 75 µg anti-mouse 
PD-L1 antibody (10F.9G2, Bio X cell) or control rat IgG2b (LTF-2, Bio X cell). Tumor 
volumes were measured every 3 days with a digital caliper, and were calculated using the 
formula: π/6 x length x width2. Body weight was measured every 5 days.  
 
2.9 Tumor cell PD-L1 expression and tumor-infiltrating lymphocyte (TIL) analysis 
EMT6 tumors were excised and digested in collagenase/hyaluronidase and DNase I, 
and dissociated by gentleMACS Dissociator as described by the protocol of tumor 
dissociation kit (Miltenyi Biotec, Auburn, CA). Tumor cells and TIL were enriched and 
harvested separately by Percoll gradient (Sigma). Cell Surface PD-L1 of Tumor cell were 
stained with Brilliant Violet 421-conjugated anti-mouse PD-L1 antibody (#124315, 
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BioLegend) and analyzed by FACS, and TIL were stained and analyzed by mass cytometry 
(CyTOF). The antibodies used to stain TIL were listed as followed: CD45-147Sm; 
CD3e-152Sm; CD4-172Yb; CD8a-168Er; IFNγ-165Ho (Fluidigm, CA). 
 
2.10 Immunohistochemical staining (IHC) of human breast tumor tissue samples 
IHC staining was performed as described previously (Lim et al., 2016). Human breast 
tumor tissue specimens were obtained following the guidelines approved by the Institutional 
Review Board at MD Anderson, and written informed consent was obtained from patients in 
all cases. Briefly, tissue specimens were incubated with antibodies against PAR (Enzo Life 
Science, Clone 10H, 1:200 dilution) and PD-L1 (Abcam, Clone 288, #ab205921, 1:100 
dilution) and a biotin-conjugated secondary antibody and then incubated with an avidin–
biotin–peroxidase complex. Visualization was performed using amino-ethylcarbazole 
chromogen. According to the histological scores, the intensity of staining was ranked into 
four groups: high (+++), medium (++), low (+) and negative (–).  
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2.11 Statistical Analysis 
Statistical analyses were performed using GraphPad Prism software (GraphPad, San 
Diego, CA). Student’s t-test or one-way analysis of variance (ANOVA) were used to 
compare experimental data. The Pearson Chi-square test were used to analyze IHC data. A P 
value < 0.05 (*) was considered statistically significant.   
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Results and Analysis 
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3.1 PARPi upregulates PD-L1 in vitro and in vivo 
3.1.1 PARPi upregulates PD-L1 in vitro 
Elevated PD-L1 expression in cancer cells has been shown to enhance PD-L1/PD-1 
axis-mediated anticancer immunosuppression (Dong et al., 2002; Reck et al., 2016). To 
determine whether inhibition of PARP affects the PD-L1 protein level, we treated 
MDA-MB-231 and BT549 cells with two different PARP inhibitors (PARPi), olaparib and 
talazoparib, and determined PD-L1 expression by immunoblotting. PARPi treatment 
increased the total level of PD-L1 protein in both cell lines (Fig. 1A). To validate whether 
PARPi-induced PD-L1 upregulation is through PARP1 inhibition, we knocked down (K/D) 
or knocked out (K/O) PARP1 in MDA-MB-231 cells. Consistent with the results shown in 
Figure 1A, PD-L1 expression in the PARP1 knockdown and knockout cells was 
substantially higher compared with the parental cells (Fig. 1B).  
PD-L1 expressed on cell surface of cancer cells exerts immunosuppressive effects by 
binding to PD-1 receptor on activated T cells (Topalian et al., 2012). To determine whether 
the level of cell surface PD-L1 increases after PARPi treatment, MDA-MB-231 cells were 
treated with or without PARPi and subjected to FACS using fluorescence-labeled PD-L1 
antibody. Cell surface PD-L1 levels have significantly increased after olaparib and 
talazoparib treatment (Fig. 1C, left panel). Likewise, cell surface PD-L1 levels were higher 
16 
in PARP1 knockdown and knockout MDA-MB-231 cells than in parental cells (Fig. 1C, 
right panel). 
 
3.1.2 PARPi upregulates PD-L1 in both BRCA proficient and deficient cancer cells 
Because PARPi is commonly used to treat BRCA-deficient cancers (Kaufman et al., 
2015), we also investigated the effects of olaparib on BRCA-mutant SUM149 cells. SUM149 
cells were treated with the different concentrations of olaparib for 10 days to mimic chronic 
PARPi exposure in clinic, and subjected to FACS to determine PD-L1 expression. Consistent 
with the results in MDA-MB-231 cells, cell surface PD-L1 was significantly increased 
following olaparib treatment in a dose-dependent manner (Fig. 1D). To further validate the 
role of BRCA deficiency in PARPi-induced PD-L1 upregulation, we knocked down BRCA1 
or BRCA2 in MDA-MB-231 cells and exposed cells to olaparib. Downregulation of BRCA1 
or BRCA2 had virtually no effect on PARPi-induced PD-L1 expression (Fig. 2). These 
results together suggested that PARPi can upregulate cell surface PD-L1 level in both 
BRCA-proficient and BRCA-deficient cells.  
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Figure 1. PARPi upregulates PD-L1 protein expression in breast cancer cells. (A) 
MDA-MDA-MB-231 and BT549 cells were treated with 10 µM olaparib or 10 nM 
talazoparib for 24 hours, and subjected to immunoblotting with the indicated antibodies. 
PD-L1 knockout (K/O) cells were included as a negative control. (B) PD-L1 expression in 
PARP1 knockdown (K/D), PARP1 knockout (K/O), and MDA-MB-231 parental cells by 
immunoblotting. (C and D) The indicated MDA-MB-231 cells were subjected to FACS 
analysis for cell surface PD-L1 expression. (E) SUM149 cells were treated with the 
indicated concentrations of olaparib for 10 days, and cell surface PD-L1 expression was 
determined by FACS.  
18 
 
 
 
 
 
 
 
 
 
 
Figure 2. Downregulation of BRCA1 or BRCA2 has no effect on PARPi-induced PD-L1 
upregulation. MDA-MB-231 cells were transfected with the indicated siRNA to knock down 
BRCA1 or BRCA2. After 36 hours of transfection, cell were treated with 10 µM olaparib for 24 
hours and subjected to FACS analysis. MDA-MB-231 cells stained with IgG-APC were set as 
isotype controls. Western blot showing BRCA knockdown by siRNA.  
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3.1.3 PARPi upregulates PD-L1 in vivo 
Next we asked whether PARPi may affects PD-L1 expression in tumors, we inoculated 
BT549 and SUM149 cells into the mammary fad pads of nude mice, and after tumor formed, 
administered olaparib to mice 5 days a week for 3 weeks. Tumor tissues from xenografts 
were isolated and subjected to immunoblotting with PD-L1 antibody. As shown, PD-L1 
expression was substantially higher in the xenograft tumors from mice treated with olaparib 
compared with those from the untreated mice (Fig. 3A and 3B). We also assessed PD-L1 
expression by IHC staining in MDA-MB-231 xenograft tumor tissues from mice that had 
been treated with another PARPi, rucaparib, and harvested from our previous study (Du et 
al., 2016). Mice treated with rucaparib for 3 weeks had higher PD-L1 expression in their 
tumors compared with control mice (Fig. 3C). Together, these results indicated that PARPi 
upregulates PD-L1 expression in TNBC in vitro and in vivo. 
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Figure 3. PARPi upregulates PD-L1 expression in xenograft tumors. (A) BT549, (B) 
SUM149 and (C) MDA-MB-231 cells were inoculated into mammary fad pad of nude mice, 
and the mice with established tumors were treated with olaparib or rucaparib. Tumors were 
then isolated to evaluate PD-L1 expression by immunoblotting (A and B) or IHC staining 
(C). Black arrowheads indicate the detected PD-L1 signals. Scale bar, 50 µm. 
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3.2 PARPi-mediated PD-L1 upregulation primarily via GSK3β inactivation 
Next, we explored the mechanism underlying PARPi-enhanced PD-L1 protein 
expression. Multiple signaling pathways, such as STAT, NF-κB and mTOR, have been 
reported to regulate PD-L1 expression level (Bellucci et al., 2013; Lim et al., 2016; Parsa et 
al., 2007). In an attempt to identify the potential signaling pathways that regulate PD-L1, we 
performed a phospho-kinase antibody array screen to identify kinases that are activated or 
inactivated following PARPi treatment. In the presence of PARPi treatment, the 
phosphorylation signal of GSK3α/β at Ser21 and Ser9, which represents its inactivated form 
(Cohen and Frame, 2001), scored the second highest after the CHK2-p53 DNA repair 
pathway (Fig. 4A). CHK2 kinase is known to respond to DNA damage, and PARPi-induced 
CHK2 phosphorylation has previously been reported (Anderson et al., 2011; Hirao et al., 
2000), further lending support to the results of our screen. The finding that PARPi 
inactivates GSK3α/β is also in line with our recent report demonstrating inactivation of 
GSK3β (p-Ser9) stabilizes PD-L1 (Li, 2016). Those findings together prompted us to 
investigate whether PARPi upregulates the expression of PD-L1 via inactivation of GSK3β. 
To this end, we examined the status of GSK3β phosphorylation at Ser9 in response to PARPi 
in SUM149 cells and BT549 cells by immunoblotting. The results indicated that PARPi 
treatment induced high GSK3β Ser9 phosphorylation that was associated with PD-L1 
22 
upregulation (Fig. 4B and 4C). Knocking out GSK3β significantly increased PD-L1 
expression (Fig. 4C, lane 3 vs. 1). However, PD-L1 expression level in GSK3β-knockout 
cells was no longer enhanced by olaparib treatment (Fig. 4C, lane 4 vs. 3). These results 
suggested that inactivation of GSK3β is required for the PARPi-induced PD-L1 
upregulation. 
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Figure 4. PARPi-mediated PD-L1 upregulation primarily via GSK3β inactivation. (A) 
SUM149 cells were treated with olaparib, and subjected to human phospho-Kinase Array. 
The top two responding kinases were Chk2 and GSK3α/β. (B) SUM149 cells were treated 
with the indicated concentrations of olaparib for 10 days, and subjected to immunoblotting 
with the indicated antibodies. (C) BT549 parental or GSK3β knockout cells were treated 
with 10 µM olaparib for 24 hours. PD-L1 expression was evaluated by immunoblotting.   
 
3.3 PARPi attenuates T-cell killing through PD-L1 induction 
3.3.1 PARPi attenuates T-cell killing 
To understand the functional significance of PD-L1 upregulation by PARPi, we first 
asked whether PARPi-induced PD-L1 increases PD-1 binding on cells. Exposure of 
MDA-MB-231 cells to olaparib induced more PD-1 binding to PD-L1 on the cell surface 
(Fig. 5A). Similar results were observed in MDA-MB-231 PARP1 K/D and K/O cells (Fig. 
5B), and in SUM149 cells treated with different concentrations of olaparib (Fig. 5C). Next, 
to determine whether PARPi-mediated PD-L1 upregulation which resulted in increased PD-1 
binding  affects T-cell function, we performed a T-cell-mediated killing assay by 
co-culturing activated human peripheral blood mononuclear cells (PBMCs) with 
MDA-MB-231 cells labeled with nuclear red fluorescence protein (RFP; NucLight Red 
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MDA-MB-231) in the presence or absence of olaparib. As expected, olaparib efficiently 
inhibited cancer cell proliferation (black vs. blue in Fig. 5D, left panel; Fig. 6A) but did not 
inhibit activated PBMCs proliferation (Fig. 6B). Interestingly, although MDA-MB-231 cells 
were sensitive to the T-cell killing (black vs. red in Fig. 5D, left panel), those that were 
treated with olaparib were strongly resistant to activated T-cell killing (blue vs. yellow in Fig. 
5D, left panel; Fig. 5D, right panel), supporting the notion that upregulation of PD-L1 by 
PARPi may render the PARPi-treated cancer cells more resistant to T-cell killing. 
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Figure 5. Olaparib increases PD-1 binding and attenuates T-cell-mediated cell death in 
TNBC cells. (A) FACS analysis of cell surface PD-1 binding of MDA-MB-231 cells treated 
with 10 µM olaparib or 10 nM talazoparib for 24 hours. (B) FACS analysis of PARP1 
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knockdown (K/D), PARP1 knockout (K/O), and parental MDA-MB-231 cells. (C) SUM149 
cells were treated with the indicated concentrations of olaparib for 10 days. (D) 
MDA-MB-231 cells expressing nuclear RFP protein were first treated with or without 
olaparib (10 µM) for 3 hours and then co-cultured with or without activated peripheral blood 
mononuclear cells (PBMCs). Left, quantitation showing the number of live cells per well, 
counting the number of red fluorescent objects, normalized to that at the zero time point. 
Right, the percent of T cell-meditated tumor cell killing observed at 72 hours in activated 
PBMC co-culture with control or olaparib-treated cells (normalized to co-culture without 
PBMCs). (E) Left, representative merged images showing red fluorescent (nuclear restricted 
RFP), and green fluorescent (Caspase 3/7 substrate) objects in MDA-MB-231 cells 
co-cultured with activated PBMCs at 0 and 72 hours. Images were taken using the IncuCyte 
Zoom microscope. Right, quantitation showing the number of live cells following treatment 
with olaparib (10 µM), PD-L1 antibody (PD-L1 Ab; 10 µg/ml), or the combination 
co-cultured with activated PBMCs for 72 hours. The number of live cells (red fluorescent 
objects) were counted and normalized to that at the zero time point. * P < 0.05; ns, not 
significant. 
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Figure 6. PARPi blocks cell proliferation of MDA-MB-231 cells but not activated 
PBMCs. (A) Representative images of MDA-MB-231 (Nuc-RFP) cells incubated with 
activated PBMCs treated with or without olaparib (10 µM) at the indicated time points. 
Images were taken using the IncuCyte Zoom microscope. (B) Activated PBMCs were 
treated with or without olaparib (10 µM). The IncuCyte Zoom microscope was used to take 
time-lapse images. 
 
3.3.2 Blockade of PD-L1 re-sensitizes cancer cells treated with PARPi to T-cell killing 
On the basis of the above results, we tested the T-cell killing effects of the combination 
of PD-L1 antibody and olaparib. The results showed that blockade of PD-L1 re-sensitized 
PARPi-treated MDA-MB-231 cells to activated T-cell killing, and that the PARPi-PD-L1 
antibody combination was more effective than each agent alone (Fig. 5E).  
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3.4 Combination with PD-L1 blockade sensitizes PARPi therapy 
Next, we sought to determine whether PD-L1 blockade could further potentiate PARPi 
anti-tumor efficacy in vivo. We first treated a murine breast cancer cell lines, EMT6, with 
olaparib with results showing significant induction of PD-L1 by olaparib (Fig. 7A). 
Consequently, we evaluated PARPi and anti-PD-L1 treatment alone or in combination in the 
EMT6 syngeneic mouse model. Consistent with our observations in vitro, both olaparib and 
anti-PD-L1 restricted tumor growth but the combined treatment demonstrated better 
therapeutic benefit than each treatment alone (Fig. 7B and 7C). There were significantly 
fewer Ki-67 positive tumor cells in the combined treatment compared with each treatment 
alone (Fig. 7D). Mice that received the combination treatment did not show any significant 
changes in body weight or elevation in liver enzyme (ALT and AST), and kidney toxicity 
marker, blood urea nitrogen (Fig. 8). At the end of treatment, tumors resected from mice 
were subjected to dissociation, and tumor cells and tumor-infiltrating lymphocytes (TIL) 
were separately harvested. Consistent with the observation in xenograft mice model (Fig. 2), 
PARPi significantly upregulated PD-L1 expression on tumor cell surface as determined by 
FACS in EMT6 syngeneic mice (Fig. 7E). Analysis of TILs by CyTOF showed that 
tumor-infiltrated cytotoxic CD8+ T-cell population, as measured by the level of IFNγ, 
decreased after PARPi treatment. Meanwhile, the addition of anti-PD-L1 restored the 
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cytotoxic CD8+ T-cell population (Fig. 8F). These results suggested that PARPi enhances 
cancer-associated immunosuppression through upregulation of PD-L1 and that PD-L1 
blockade potentiates PARPi therapy.  
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Figure 7. PARPi-induced PD-L1 upregulation suppresses anticancer immunity and 
blockade of PD-L1 potentiates PARPi. (A) EMT6 cells were treated with 10 µM olaparib 
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for 24 h. Cell surface PD-L1 were analyzed by FACS. (B) Representative images of tumors 
after olaparib and/or anti-PD-L1 antibody treatment at the indicated time points in the EMT6 
syngeneic mouse model. (C) Effects of olaparib and/or anti-PD-L1 antibody treatment on 
tumor growth in EMT6 syngeneic mouse model treated (n = 8). Tumors were measured at 
the indicated time points and dissected for tumor cell PD-L1 expression analysis, TIL 
analysis, and pathological analysis at endpoint. (D) Hematoxylin and eosin (H&E) and 
Ki-67 staining of EMT6 tumors. Scale bar, 50 µm. (E) Cell surface PD-L1 expression in 
EMT6 cells derived from EMT6 mouse tumors. (F) Cytotoxic CD8+ T cells population 
(IFNγ+ CD8+ CD3+ CD45+) in TILs isolated from EMT6 tumors by CyTOF analysis. * P < 
0.05 
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Figure 8. Toxicity assessment of treatment on BALB/c mice. The body weight was 
measured every 5 days, and mice liver, and kidney functions were tested at the end of the 
experiments. BUN, blood urea nitrogen; ALT, alanine aminotransferase; AST, aspartate 
aminotransferase. 
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3.5 Correlations of PARylation and PD-L1 expression in human tumor tissues 
PARP exerts its biological function through its PARylation enzyme activity, and PARP 
inhibitors are designed to inhibit its enzyme activity. Thus, the extent of protein PARylation 
was utilized to assess the efficacy of PARP inhibition (Kummar et al., 2011). To further 
validate our findings in human cancer patient samples, we analyzed the correlations between 
PARylation level and PD-L1 expression in human breast tumor specimens using IHC. High 
level of protein PARylation was detected in 87 (75.0%) of the 116 specimens, of which 65 
(74.7%) cases showed low PD-L1 expression (Figure 9, top). The Pearson Chi-Square test 
further showed the inverse correlation between PARylation level and PD-L1 expression 
exists in human cancer patient specimens (Figure 9, bottom). These results supported the 
notion that high PARP enzyme activity suppresses PD-L1 expression.   
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Figure 9. Inverse correlation between PAR and PD-L1 in surgical specimens of breast 
cancer. Top, representative images of IHC staining of PAR and PD-L1 in human breast 
cancer tissues (n = 116). Scale bar, 50 µm. Bottom, correlation analysis between PAR and 
PDL-1 was analyzed using the Pearson Chi-Square test (P = 0.02). A P value of less than 
0.05 was considered to be statistically significant. 
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3.6 PARPi treatment increases T lymphocytes infiltration in tumors 
IHC staining of CD3 demonstrates that EMT6 tumors under PARPi treatment showed 
increased T cell infiltration compared with those under control treatment (Fig. 10). The 
potential reasons may be: PARPi promotes cancer cell death via its cytotoxic effects to 
release more antigens and attract lymphocytes infiltration; as a DNA repair enzyme inhibitor, 
PARPi may lead to more DNA damage, increase the mutation burden and promote 
neo-antigen generation.   
As shown in Fig. 7F, PARPi treatment decrease the percentage of cytotoxic CD8 T 
cells population (indicated as IFNγ+ CD8+ T population) against total CD8 T cells, partly 
due to the PARPi-mediated upregulation of PD-L1 on cancer cells. Taken together, these 
data indicate that on one hand PARPi increases T lymphocyte infiltration in tumors; however 
on the other hand PARPi upregulates PD-L1 expression on tumor cells which limits the 
anti-tumor effects of the infiltrating T lymphocytes, indicated by lower cytotoxic CD8 T cell 
percentage. Therefore, the addition of PD-L1 or PD-1 blockade to PARPi therapy can 
greatly improve the anti-tumor effects via attenuating the cancer-associated 
immunosuppression.   
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Figure 10. PARPi treatment increases T lymphocytes infiltration in EMT6 tumors. IHC 
staining of CD3 in mouse tumor tissues from three EMT6 syngeneic BABL/c mice (A, B 
and C) under control treatment, or (D, E and F) under PARPi treatment. Three representative 
black arrows in each panel indicate detected CD3 signals.   
  
3.7 PARPi upregulates PD-L1 in specific cancer cell lines  
Fig. 2 and 3 showed that PARPi can upregulate in three breast cancer cell lines, 
MDA-MB-231, BT549 and SUM149. However, cell surface level of PD-L1 was not 
upregulated in one breast cancer cell line T47D after PARPi treatment (Fig. 11B). Since 
PARPi is clinically used in ovarian cancer and also shows promising clinical benefit in 
prostate cancer demonstrated by late-stage clinical trials, ovarian cancer cell lines HOC7 and 
OVCA433, and prostate cancer cell lines PC3 and DU145 were further tested. PARPi 
mediated PD-L1 upregulation can be observed in HOC7 and PC3 cells but not OVCA433 or 
DU145 cells (Fig. 11A). H460, HELA and U2OS were also treated with 10 µM olaparib for 
72 h. It showed that olaparib can upregulate PD-L1 in HELA and U2OS cells. In addition, in 
murine breast cancer cell lines, there is a more obvious induction of PD-L1 by olaparib in 
EMT6 cells compared with 4T1 cells (Fig. 12). In sum, PARPi upregulates PD-L1 in 
specific cancer cell lines.  
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Figure 11. PARPi upregulates PD-L1 expression in specific cancer cell lines. (A) Ovarian 
cancer cell lines HOC7 and OVCA433, and prostate cancer cell lines PC3 and DU145 were 
treated with 10 µM olaparib for 72 h. Cell surface PD-L1 were measured by FACS analysis. 
Olaparib can induce PD-L1 upregulation in HOC7 and PC3 cancer cells but not OVCA433 
or DU145 cells. (B) H460, T47D, HELA and U2OS were treated with 10 µM olaparib for 72 
h. Olaparib can upregulate PD-L1 in HELA and U2OS cells. 
 
 
 
 
 
 
 
Figure 12. A more obvious induction of PD-L1 was observed in EMT6 cancer cells 
compared with 4T1 cells. Murine breast cancer cells were treated with 10 µM olaparib for 
72 h 
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Chapter 4  
Conclusion and Discussion 
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Although the cytotoxic effects of PARPi have been well studied, the role of PARP 
inhibition in cancer-associated immunity is still largely unknown. In this study, we 
demonstrated that PARPi upregulates PD-L1 expression primarily through GSK3β 
inactivation. PARPi renders cancer cells more resistant to T-cell-mediated cell death, and 
PD-L1 blockade potentiates PARPi in vitro and in vivo. These data strongly suggested that 
PD-L1 upregulation by PARPi treatment attenuates PARPi therapeutic efficacy via 
tumor-associated immunosuppression, and simultaneous inhibition of PARP and PD-L1 may 
benefit breast cancer patients. There are currently three clinical trials testing the combination 
of PARPi (olaparib, niraparib, and BGB-290) and PD-L1 or PD-1 antibody in multiple 
cancer types (NCT02484404; NCT02657889; NCT02660034). The results of the current 
study provided scientific basis for these clinical trials.  
Higuchi et al. recently investigated the combination of PARPi and CTLA4 antibody in 
the BR5-AKT ovarian cancer syngeneic mouse model and claimed to have observed a 
synergistic therapeutic effect (Higuchi et al., 2015); however, they indicated they did not 
observe such synergistic effect using the anti-PD-1 and PARPi combination in the same 
animal model. It is worthwhile to mention that PD-1 blockade in the BR5-AKT syngeneic 
mice did not affect T-cell activation or cytokine induction in the peritoneal tumor 
environment in their study [28], and therefore, synergistic effects may not be observed in 
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combination with PARPi under their experimental condition. In contrast, the results from our 
study indicated that PARPi upregulates PD-L1 in EMT6 tumors and PD-L1 blockade 
attenuated immunosuppression activity (Fig. 5F), which allowed us to observe an 
anti-PD-L1 therapy-potentiated antitumor activity of PARPi. Meanwhile, other studies have 
reported that chemotherapeutic agents, gemcitabine and paclitaxel, can induce PD-L1 in 
ovarian cancer cells (Ding et al., 2014; Peng et al., 2015). The combination of paclitaxel and 
PD-L1/PD-1 blockade enhanced antitumor efficacy in an ID8 ovarian syngeneic mouse 
model (Peng et al., 2015). Therefore, whether the combination of PD-L1 blockade and 
PARPi induces synergistic effect in ovarian cancer warrants further investigation in a 
suitable animal model. Nonetheless, the mechanism of interaction between PARP and 
PD-L1/PD-1 as shown in the current study is timely and provides scientific basis to develop 
more effective combination therapies consisting of two powerful anti-cancer agents.  
In this study, it has been shown that PARPi treatment increases T lymphocytes 
infiltration in syngeneic mouse tumors. However, the PARPi-induced PD-L1 on tumor cells 
serves as “side effects”, inhibits the T cell activation and attenuates the anti-tumor effects of 
the infiltrating T lymphocytes. Therefore, the addition of anti-PD-L1 or anti-PD-1 therapy to 
PARPi can greatly enhance therapeutic efficacy via blocking the cancer-associated 
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immunosuppression. However, the underlying mechanisms of how PARPi increases T cell 
infiltration needs further study. 
It has also been observed that PARPi-mediated PD-L1 induction is applied to specific 
cancer cell lines. It is quite possible that human tumors that treated with PARPi can be 
classified as tumors with PD-L1 induction or those without induction. Future studies should 
focus on the unique features of the tumors with or without PARPi-mediated PD-L1 induction, 
and consequently identify biomarkers to distinguish the two types of tumors. Tumors with 
PD-L1 induction after PARPi treatment should benefit more from the combination of PD-L1 
or PD-1 blockade and PARPi. Therefore, the identified biomarkers can be used to stratify 
patients for the anti-PD-L1/ PD-1 and PARPi combination therapy.     
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